MCID: ACT135
MIFTS: 51

Acute Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 20 58
Acute Graft-Versus-Host Disease 54
Acute Gvh Disease 70
Acute Gvhd 20

Classifications:

Orphanet: 58  
Rare immunological diseases


External Ids:

ICD10 via Orphanet 33 T86.0
UMLS via Orphanet 71 C0856825
Orphanet 58 ORPHA99920
UMLS 70 C0856825

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to graft-versus-host disease and chronic graft versus host disease. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Infliximab and Daclizumab have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and t cells, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 605)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 31.9 TNF IL2 IL10 IFNG FASLG ARHGAP45
2 chronic graft versus host disease 31.6 IL2RA IL10 IFNG
3 post-transplant lymphoproliferative disease 31.1 TNF IL10
4 mucositis 31.0 IL2 IL10 CSF3
5 bronchiolitis obliterans 30.8 TNF IL10 IFNG
6 bronchitis 30.7 TNF IL4 IL10
7 exanthem 30.7 TNF IL2 IL18 IL10 IFNG CSF3
8 hypereosinophilic syndrome 30.7 IL4 IL2RA IL2 IFNG
9 lymphoproliferative syndrome 30.7 IL2RA IL2 IL10 FASLG
10 pemphigoid 30.7 TNF IL4 IFNG
11 pancytopenia 30.5 IL2RA IFNG CSF3
12 neutropenia 30.5 TNF IL2 IL10 FASLG CSF3
13 bronchiolitis 30.5 TNF IL4 IL18 IL10 IFNG
14 alopecia 30.5 TNF IL4 IL2 IFNG
15 amebiasis 30.4 TNF IL4 IL10
16 hemorrhagic cystitis 30.4 TNF IL2 CSF3
17 pemphigus 30.4 TNF IL4 IL10
18 leukemia, acute myeloid 30.4 TNF IL4 IL2 IL10 FASLG CSF3
19 lymphoma, hodgkin, classic 30.3 IL2RA IL2 CSF3
20 enterocolitis 30.3 TNF IL10
21 cystitis 30.3 TNF IL4 IL2 IL18
22 myelodysplastic syndrome 30.3 TNF IL2 IL10 IFNG FASLG CSF3
23 skin disease 30.3 TNF IL4 IL2 IL18 IL10 IFNG
24 cholera 30.3 TNF IL4 IL10
25 acute pancreatitis 30.3 TNF IL18 IL10
26 adult t-cell leukemia 30.3 IL4 IL2RA IL2
27 diarrhea 30.3 TNF NOD2 IL2 IL10 IFNG CSF3
28 bilirubin metabolic disorder 30.3 TNF IL2 CSF3
29 erythema multiforme 30.2 TNF IL4 IL2 IFNG FASLG
30 chickenpox 30.2 TNF IL4 IL2 IL10 IFNG
31 conjunctivitis 30.2 TNF IL4 IL2 IL10 IFNG
32 toxic shock syndrome 30.2 TNF IL4 IL2 IL10 IFNG
33 systemic scleroderma 30.2 TNF IL4 IL10 IFNG
34 keratoconjunctivitis 30.2 TNF IL4 IL2 IFNG
35 invasive aspergillosis 30.2 NOD2 IL10 IFNG CSF3
36 myeloma, multiple 30.2 TNF IL2 IL10 CSF3
37 liver cirrhosis 30.2 TNF IL2 IL10 IFNG
38 proteasome-associated autoinflammatory syndrome 1 30.2 TNF IL4 IL18 IL10 IFNG
39 urticaria 30.2 TNF IL4 IL18 IL10
40 lymphopenia 30.2 IL4 IL2RA IL2 IL10 IFNG FASLG
41 bacterial pneumonia 30.1 TNF IL10 CSF3
42 bacterial infectious disease 30.1 TNF NOD2 IL18 IL10 IFNG CSF3
43 severe combined immunodeficiency 30.0 IL4 IL2RB IL2RA IL2 IL10 IFNG
44 diphtheria 30.0 TNF IL4 IL2RB IL2RA IL2
45 localized scleroderma 30.0 TNF IL4 IL2
46 bacterial sepsis 30.0 TNF IL18 IL10
47 lichen planus 30.0 TNF IL4 IL2 IL10 IFNG
48 pneumonia 30.0 TNF IL4 IL10 IFNG CSF3
49 b cell deficiency 29.9 TNF IL4 IL2 IL10
50 cutaneous t cell lymphoma 29.8 IL4 IL2RB IL2RA IL2 IFNG

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.61 IL2 NOD2
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.61 FASLG IL10 IL18 IL2 IL2RA NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 IL10 IL18 IL2RA TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 IL10 IL18 IL2 IL2RA NOD2 TNF

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.18 FASLG IFNG IL10 IL18 IL2 IL2RA
2 hematopoietic system MP:0005397 10.18 CSF3 FASLG IFNG IL10 IL18 IL2
3 cellular MP:0005384 10.15 FASLG IFNG IL10 IL18 IL2 IL4
4 immune system MP:0005387 10.15 CSF3 FASLG IFNG IL10 IL18 IL2
5 growth/size/body region MP:0005378 10.13 IFNG IL10 IL18 IL2 IL2RA IL2RB
6 endocrine/exocrine gland MP:0005379 10.06 FASLG IFNG IL10 IL2 IL2RA IL2RB
7 integument MP:0010771 9.97 CSF3 FASLG IFNG IL10 IL18 IL2RB
8 mortality/aging MP:0010768 9.9 FASLG IFNG IL10 IL18 IL2 IL2RA
9 liver/biliary system MP:0005370 9.86 FASLG IFNG IL10 IL2 IL2RB IL4
10 respiratory system MP:0005388 9.56 FASLG IFNG IL10 IL2 IL2RA IL4
11 vision/eye MP:0005391 9.23 FASLG IFNG IL10 IL18 IL2 IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
3 Gastrointestinal Agents Phase 4
4 Immunosuppressive Agents Phase 4
5 Antirheumatic Agents Phase 4
6 Dermatologic Agents Phase 4
7
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
8
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
9
Protein C Approved Phase 2, Phase 3
10
leucovorin Approved Phase 3 58-05-9 6006
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
12
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
13
Vancomycin Approved Phase 3 1404-90-6 14969 441141
14
Mycophenolic acid Approved Phase 3 24280-93-1 446541
15
Pentostatin Approved, Investigational Phase 3 53910-25-1 439693 40926
16
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616
17
Methoxsalen Approved Phase 3 298-81-7 4114
18
Basiliximab Approved, Investigational Phase 3 152923-56-3, 179045-86-4
19
alemtuzumab Approved, Investigational Phase 3 216503-57-0
20
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
21
carbamide peroxide Approved Phase 3 124-43-6
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Cysteine Approved, Nutraceutical Phase 3 52-90-4 5862
24
Inolimomab Investigational Phase 3 152981-31-2 5785
25 Interferon alpha-2 Phase 2, Phase 3
26 Interferon-alpha Phase 2, Phase 3
27 interferons Phase 2, Phase 3
28 Acidophilus Phase 3
29 Vitamin B9 Phase 3
30 Folic Acid Antagonists Phase 3
31 Folate Phase 3
32 Vitamin B Complex Phase 3
33 Triamcinolone diacetate Phase 3
34 triamcinolone acetonide Phase 3
35 Triamcinolone hexacetonide Phase 3
36 Antilymphocyte Serum Phase 3
37 Neuroprotective Agents Phase 2, Phase 3
38 Hormone Antagonists Phase 2, Phase 3
39 Antiemetics Phase 2, Phase 3
40 Hormones Phase 2, Phase 3
41 Antineoplastic Agents, Hormonal Phase 2, Phase 3
42 glucocorticoids Phase 2, Phase 3
43 Anti-Inflammatory Agents Phase 2, Phase 3
44 Protective Agents Phase 2, Phase 3
45 Pharmaceutical Solutions Phase 3
46 Serine Proteinase Inhibitors Phase 2, Phase 3
47 Alpha 1-Antitrypsin Phase 2, Phase 3
48 Protein C Inhibitor Phase 2, Phase 3
49
protease inhibitors Phase 2, Phase 3
50 Trypsin Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 231)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
3 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
4 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
5 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
6 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
7 Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2 Unknown status NCT03887156 Phase 2, Phase 3
8 Total Body Irradiation Dose De-escalation Study in Patients With Fanconi Anemia Undergoing Alternate Donor Hematopoietic Cell Transplantation Completed NCT00352976 Phase 2, Phase 3 Cyclophosphamide;Fludarabine;Mycophenolate Mofetil;Sirolimus
9 The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
10 Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02652130 Phase 3
11 GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease Completed NCT03139604 Phase 3 Itacitinib;Placebo;Prednisone;Methylprednisolone
12 A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
13 A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
14 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
15 A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT00366145 Phase 3 Standard of Care for GVHD
16 A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02336230 Phase 3 remestemcel-L
17 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
18 Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation Recruiting NCT02634294 Phase 2, Phase 3 Peg interferon alfa-2b
19 A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) Recruiting NCT03805789 Phase 2, Phase 3
20 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03657160 Phase 3 Vedolizumab;Vedolizumab Placebo
21 The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) Recruiting NCT03057054 Phase 3
22 Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells Recruiting NCT03631589 Phase 2, Phase 3
23 A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-versus-host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT04095858 Phase 3 CD24Fc;Placebo;Methotrexate;Tacrolimus
24 A Multi-center Randomized in Double-blinded Phase III Study Comparing Standard Care Therapy Alone Versus Corticosteroids and Low-dose Methotrexate (MTX) for the First-line Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Recruiting NCT03371667 Phase 3 Methotrexate;Placebo
25 A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant Recruiting NCT04167514 Phase 3 Placebo
26 Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease Active, not recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
27 Evaluation of the Efficacy of MaaT013 as Salvage Therapy in Acute GVHD Patients With Gastrointestinal Involvement, Refractory to Ruxolitinib; a Multi-center Open-label Phase III Trial. Not yet recruiting NCT04769895 Phase 3 MaaT013
28 A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial) Not yet recruiting NCT04629833 Phase 3
29 A Phase 3, Multicenter, Open Label, Study to Evaluate the EFficacy and SaFEty of Leukotac® (Inolimomab) in Pediatric Patients With Steroid Resistant Acute Graft Versus Host Disease (SR-aGvHD) Not yet recruiting NCT04289103 Phase 3
30 Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD) Terminated NCT02524847 Phase 3 Methoxsalen
31 A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease Terminated NCT00282503 Phase 3 Methoxsalen+ECP, Methylprednisolone
32 An Open-Label, Single-Arm, Multicenter Study, of Combination Anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease. Terminated NCT04128319 Phase 3 T-Guard
33 A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects With Acute Graft-Versus-Host Disease With Lower Gastrointestinal Involvement Terminated NCT02956122 Phase 2, Phase 3 methylprednisolone or equivalent steroid
34 Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease Terminated NCT02411084 Phase 3
35 Open-Label, Single-Center, Self Control, Phase Ⅰ/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Acute Graft-versus-host Disease Unknown status NCT01754454 Phase 1, Phase 2
36 A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation Unknown status NCT01589549 Phase 2
37 Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation Unknown status NCT01596075 Phase 1, Phase 2 Cannabidiol
38 Chidamide Plus Post-transplantation Cyclophosphamide and Cyclosporine to Prevent Graft-versus-host Disease After Myeloablative Conditioning, Matched Peripheral-blood Stem-cell Transplantation Unknown status NCT03336632 Phase 2 Chidamide;Cyclophosphamide;cyclosporine A
39 Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Acute Graft-versus-host Disease Unknown status NCT01765634 Phase 2
40 Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease Unknown status NCT02392780 Phase 2 Cannabidiol;Methylprednisolone;Calcineurin inhibitor
41 A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease Unknown status NCT00032279 Phase 2 Visilizumab
42 An Open-Label, Single-Arm, Phase II Multicenter Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Reduced Intensity Conditioning (RIC) Allogeneic Stem-Cell Transplantation Unknown status NCT02737306 Phase 2 PRO 140
43 Evaluation of Extracorporeal Photochemotherapy in Children and Young Adults With Refractory Acute Graft Versus Host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT00824954 Phase 2
44 A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT) Unknown status NCT02406651 Phase 1, Phase 2 Recombinant Human Interleukin-22 IgG2-Fc (F-652);Systemic Corticosteroids
45 Direct Intra Bone Marrow Injection Of Unrelated Cord Blood Cells To Improve Engraftment And Reduce Acute Graft-Versus-Host Disease Unknown status NCT00696046 Phase 1, Phase 2
46 Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation Unknown status NCT01941394 Phase 2
47 Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease Unknown status NCT02172937 Phase 1, Phase 2
48 Phase 1/2a, Multicenter, Open-Label Study Designed to Evaluate the Safety, Tolerability and Preliminary Efficacy of ApoCell Administration, a Donor Apoptotic Cell-Based Product, for the Prevention of Acute Graft Versus Host Disease (GvHD) in Subjects With Hematologic Malignancies Undergoing Allogeneic Sibling HLA-Matched Hematopoietic Stem Cell Transplantation (HSCT) Unknown status NCT00524784 Phase 1, Phase 2
49 Phase II Study of Valproic Acid With Methylprenisonlone for the Treatment of Grade II-IV Acute GVHD in Patients After Allogeneic Stem Cell Transplantation Unknown status NCT02848105 Phase 2 VPA
50 Treatment of Steroid-refractory Acute and Chronic Graft-versus-host Disease With Inhibitor of Janus Kinases Completed NCT02997280 Phase 2 Ruxolitinib Oral Tablet

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

40
Bone Marrow, Myeloid, T Cells, Bone, Endothelial, Skin, Nk Cells

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 8952)
# Title Authors PMID Year
1
Investigation of functional IL-10 gene polymorphism and IL-10 levels in acute graft-versus-host disease. 61 54
20195716 2010
2
[Correlation of donor and recipient serum interleukin 2 and tumor necrosis factor alpha levels to acute graft-versus-host disease in hematopoietic stem cell transplantation]. 54 61
20423859 2010
3
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. 54 61
19896079 2009
4
Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism. 54 61
19740324 2009
5
Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors. 54 61
19326415 2009
6
Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. 61 54
18081874 2009
7
IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. 54 61
19295315 2009
8
Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. 54 61
18721759 2008
9
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. 61 54
18541197 2008
10
Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host disease. 54 61
18360276 2008
11
[Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells]. 61 54
18681307 2008
12
[A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation]. 54 61
18681306 2008
13
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. 61 54
17827036 2008
14
[Effect of granulocyte colony-stimulating factor on immunological regulation and its application in allogenic hematopoietic stem cell transplantation]. 54 61
17956704 2007
15
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. 61 54
17465640 2007
16
[Changes of IL-2, IL-8, IL-10 and TNF-alpha levels in sera of patients with acute graft-versus-host disease]. 54 61
16928315 2006
17
Costs of allogeneic hematopoietic stem cell transplantation. 54 61
16858272 2006
18
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome. 54 61
17325958 2006
19
Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. 54 61
16699531 2006
20
Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. 54 61
16565744 2006
21
[Influence of G-CSF mobilization on functions of donor T lymphocyte subpopulation and acute graft-versus-host disease]. 54 61
16584603 2006
22
Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. 54 61
16436969 2006
23
Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. 54 61
16431290 2006
24
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. 54 61
16131567 2005
25
Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. 61 54
16109775 2005
26
Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. 61 54
16210965 2005
27
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. 61 54
16125638 2005
28
Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 61 54
16125640 2005
29
Limiting dilution analysis of interleukin-2 producing helper T-cell frequencies as a tool in allogeneic hematopoietic cell transplantation. 54 61
16177628 2005
30
Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. 61 54
16098072 2005
31
NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation. 54 61
15935882 2005
32
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. 54 61
15744237 2005
33
Hyperuricemia and bone marrow transplantation. 54 61
15604610 2005
34
Genetic polymorphisms predicting the outcome of bone marrow transplants. 61 54
15566351 2004
35
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. 61 54
15548717 2004
36
Interleukin-18: recent advances. 54 61
15548995 2004
37
Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. 54 61
15280194 2004
38
Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. 61 54
15327523 2004
39
Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. 61 54
15449032 2004
40
Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. 54 61
15235581 2004
41
Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in recipients of allogeneic hematopoietic stem cell transplants. 61 54
15467488 2004
42
Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation. 54 61
15194539 2004
43
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 54 61
14691124 2004
44
Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation. 61 54
14663280 2003
45
G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. 61 54
12676791 2003
46
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. 54 61
12433681 2003
47
Roles of interleukin-10 in acute graft-versus-host disease and graft rejection. 61 54
12875717 2003
48
TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model. 61 54
12598909 2003
49
Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. 54 61
12476283 2002
50
Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. 54 61
12393699 2002

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TNFRSF4 TNF NOD2 IL4 IL2RB IL2RA
2
Show member pathways
13.83 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
3
Show member pathways
13.68 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
4
Show member pathways
13.53 TNF IL4 IL2RB IL2RA IL2 IL18
5
Show member pathways
13.44 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
6
Show member pathways
13.31 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
7
Show member pathways
13.26 TNFRSF4 TNF NOD2 IL4 IL2RB IL2RA
8
Show member pathways
13.2 TNF IL4 IL2RB IL2RA IL2 IFNG
9
Show member pathways
13.2 TNF IL2 IL18 IL10 IFNG FASLG
10
Show member pathways
13.05 TNF IL4 IL2RB IL2RA IL2 FASLG
11
Show member pathways
12.93 TNF IL4 IL2RA IL2 IL10 IFNG
12
Show member pathways
12.9 TNF IL2RB IL2RA IL2 IL18 IFNG
13 12.88 IL4 IL2RB IL2RA IL2 IFNG FASLG
14
Show member pathways
12.79 TNF IL4 IL2RB IL2RA IL2
15
Show member pathways
12.73 TNF IL4 IL2RA IL2 IL18 IL10
16
Show member pathways
12.65 TNF NOD2 IL4 IL2RB IL2RA IL2
17
Show member pathways
12.64 TNF IL4 IL2 IL10 IFNG
18
Show member pathways
12.63 TNF IL2 IL18 IL10 IFNG
19 12.6 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
20
Show member pathways
12.56 TNF IL4 IL2 IFNG FASLG
21
Show member pathways
12.5 IL4 IL2RB IL2RA IL2 IL10 IFNG
22
Show member pathways
12.44 TNF IL2RB IL2RA IL2 IL18 IL10
23 12.36 TNF IL2RB IL2RA IL2
24
Show member pathways
12.36 TNF IL4 IFNG CSF3
25
Show member pathways
12.36 TNF IL4 IL2RA IL2 IL18 IL10
26
Show member pathways
12.35 TNF IL4 IL2 IFNG
27 12.33 TNF NOD2 IL18 IL10 IFNG
28
Show member pathways
12.29 TNF IL4 IL10 IFNG
29
Show member pathways
12.22 TNF IL4 IFNG FASLG
30 12.14 TNF IL2 IL18 IL10
31
Show member pathways
12.13 IL2RB IL2RA IL2 IFNG
32 12.11 TNF IL4 IL18 IL10 FASLG
33 12.07 TNF IL4 IL2 IFNG
34
Show member pathways
12.07 IL4 IL2RB IL2RA IL2 IL18 IFNG
35 11.98 TNF IL4 IL2RA CSF3
36 11.92 TNF IL10 IFNG
37 11.92 TNF IL4 IL2RB IL2RA IL2 IL10
38
Show member pathways
11.9 TNF IL2 IL18 IL10 IFNG
39 11.88 TNF IL18 IFNG
40 11.85 TNF IL2 IL10 IFNG
41
Show member pathways
11.85 TNF IL4 IL2RA IL2 IFNG FASLG
42
Show member pathways
11.84 IL4 IL2RB IL2RA IL2 FASLG
43 11.83 IL4 IL2RB IL2RA IL2
44 11.83 TNFRSF4 TNF IL4 IL2RA IL10
45
Show member pathways
11.82 TNFRSF4 TNF FASLG
46 11.82 IL4 IL2 IFNG
47
Show member pathways
11.7 TNF IL2 IFNG
48 11.7 TNF IL4 CSF3
49 11.68 TNF IL18 IL10 IFNG CSF3
50 11.67 TNF IL2 IFNG FASLG

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNF IL4 IL2 IL18 IL10 IFNG
2 external side of plasma membrane GO:0009897 9.72 TNFRSF4 TNF IL2RB IL2RA FASLG
3 extracellular region GO:0005576 9.61 TNF IL4 IL2 IL18 IL10 IFNG
4 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA
5 cell surface GO:0009986 9.1 TNFRSF4 TNF NOD2 IL2RB IL2RA FASLG

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 IL4 IL2RB IL18 IL10 FASLG CSF3
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 TNF NOD2 IL4 IL2 IL18 IL10
3 inflammatory response GO:0006954 10.03 TNFRSF4 TNF IL2RA IL18
4 positive regulation of cell proliferation GO:0008284 10 NOD2 IL4 IL2 IFNG FASLG CSF3
5 cellular response to lipopolysaccharide GO:0071222 9.93 TNF NOD2 IL10 CSF3
6 MAPK cascade GO:0000165 9.93 TNF IL2RB IL2RA IL2 IL18
7 tumor necrosis factor-mediated signaling pathway GO:0033209 9.9 TNFRSF4 TNF FASLG
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.89 TNF IL10 CSF3
9 negative regulation of inflammatory response GO:0050728 9.89 IL4 IL2RA IL2 IL10
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 TNF IL18 CSF3
11 positive regulation of interleukin-6 production GO:0032755 9.88 TNF NOD2 IFNG
12 negative regulation of tumor necrosis factor production GO:0032720 9.86 NOD2 IL4 IL10
13 cellular response to organic cyclic compound GO:0071407 9.86 TNF NOD2 IL18
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF NOD2 IL18
15 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL2 IL18
16 positive regulation of T cell proliferation GO:0042102 9.85 IL4 IL2RA IL2
17 positive regulation of interleukin-1 beta production GO:0032731 9.82 TNF NOD2 IFNG
18 positive regulation of cytokine production GO:0001819 9.81 TNF IL10 IFNG
19 extrinsic apoptotic signaling pathway GO:0097191 9.81 TNF IFNG FASLG
20 positive regulation of B cell proliferation GO:0030890 9.8 TNFRSF4 IL4 IL2
21 positive regulation of inflammatory response GO:0050729 9.78 TNF IL2 IL18 IFNG
22 microglial cell activation GO:0001774 9.74 TNF IL4 IFNG
23 positive regulation of amyloid-beta formation GO:1902004 9.73 TNF IFNG
24 negative regulation of interleukin-12 production GO:0032695 9.73 NOD2 IL10
25 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.72 NOD2 IFNG
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF IFNG
27 astrocyte activation GO:0048143 9.72 TNF IFNG
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 TNF IL10
29 positive regulation of activated T cell proliferation GO:0042104 9.72 IL2RA IL2 IL18
30 positive regulation of signaling receptor activity GO:2000273 9.71 IL10 IFNG
31 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL18
32 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
33 negative regulation of T-helper 17 cell differentiation GO:2000320 9.7 IL4 IL2
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.7 IL4 IL2
35 necroptotic signaling pathway GO:0097527 9.69 TNF FASLG
36 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
37 positive regulation of T cell differentiation GO:0045582 9.69 IL4 IL2RA IL2
38 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
39 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2RA IL2
40 positive regulation of tissue remodeling GO:0034105 9.67 IL2 IL18
41 positive regulation of immunoglobulin production GO:0002639 9.67 TNFRSF4 IL2 IL10
42 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.66 TNF NOD2
43 negative regulation of cytokine production involved in immune response GO:0002719 9.66 TNF IL10
44 positive regulation of cellular respiration GO:1901857 9.65 IL4 IFNG
45 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
46 negative regulation of interleukin-18 production GO:0032701 9.65 NOD2 IL10
47 positive regulation of interleukin-17 production GO:0032740 9.63 NOD2 IL2 IL18
48 positive regulation of plasma cell differentiation GO:1900100 9.62 IL2 IL10
49 positive regulation of phagocytosis GO:0050766 9.62 TNF NOD2 IL2RB IFNG
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL4 IL2 IL10 CSF3
2 cytokine activity GO:0005125 9.23 TNF IL4 IL2 IL18 IL10 IFNG
3 interleukin-2 binding GO:0019976 9.16 IL2RB IL2RA
4 interleukin-2 receptor activity GO:0004911 8.96 IL2RB IL2RA

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....